Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
06 mai 2021 16h04 HE
|
Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
28 sept. 2020 08h45 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
15 sept. 2020 07h18 HE
|
Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
25 août 2020 06h30 HE
|
Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration
21 nov. 2019 04h00 HE
|
Harpoon Therapeutics; AbbVie Inc.
Harpoon grants AbbVie option to license worldwide rights to HPN217 (BCMA), a TriTAC for the treatment of multiple myeloma planned for IND filing this year Expanded TriTAC discovery collaboration...
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Allergan plc (NYSE: AGN) on Behalf of Allergan Shareholders and Encourages Allergan Investors to Contact the Firm
26 juin 2019 16h32 HE
|
Bragar Eagel & Squire
NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Allergan plc (NYSE: AGN) on behalf of Allergan...
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
07 mai 2019 07h23 HE
|
Aptinyx Inc.
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies
22 févr. 2019 08h00 HE
|
Voyager Therapeutics, Inc.
Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1...
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
20 nov. 2018 12h37 HE
|
Schall Law
LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...
INVESTOR REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
12 nov. 2018 09h10 HE
|
Schall Law
LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AbbVie Inc. (“AbbVie” or...